Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion - PubMed
6 hours ago
- #Mantle cell lymphoma
- #Personalized treatment
- #BTKi
- Mantle cell lymphoma (MCL) is a rare and aggressive subtype of non-Hodgkin B-cell lymphoma.
- Recent advancements include Bruton's tyrosine kinase inhibitors (BTKi), CAR-T therapy, and chemo-free regimens.
- The article explores the role of autologous stem cell transplantation (ASCT) and alternatives for ineligible patients.
- Personalized treatment approaches are emphasized, considering genetic markers, comorbidities, and regional resources.
- BTKi is highlighted as an effective first-line option for ASCT-ineligible patients.
- Global collaboration is crucial for advancing MCL treatment and ensuring optimal care.